Company · CIK 0001658247 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
Crinetics Pharmaceuticals, Inc. · CRNX
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2026 DForm 4 → | Sep 1, 5:02 pm EDT | Wendell WierengaDirector | 122,071 | $85.00 | $10,376,035 | 0 | — | |
| Sep 1, 2026 DForm 4 → | Sep 1, 5:02 pm EDT | Coelho Rogerio VivaldiDirector | 19,225 | $85.00 | $1,634,125 | 0 | — | |
| Sep 1, 2026 DForm 4 → | Sep 1, 5:01 pm EDT | Stephanie OkeyDirector | 12,325 | $85.00 | $1,047,625 | 0 | — | |
| Sep 1, 2026 DForm 4 → | Sep 1, 5:01 pm EDT | Weston NicholsDirector | 22,225 | $85.00 | $1,889,125 | 0 | — | |
| Sep 1, 2026 DForm 4 → | Sep 1, 5:01 pm EDT | Matthew K FustDirector | 28,761 | $85.00 | $2,444,685 | 0 | — | |
| Sep 1, 2026 DForm 4 → | Sep 1, 5:00 pm EDT | Caren DeardorfDirector | 22,225 | $85.00 | $1,889,125 | 0 | — | |
| Sep 1, 2026 DForm 4 → | Sep 1, 5:00 pm EDT | Camille L BedrosianDirector | 22,225 | $85.00 | $1,889,125 | 0 | — | |
| Sep 1, 2026 DForm 4 → | Sep 1, 4:55 pm EDT | Isabel KalofonosChief Commercial Officer | 35,669 | $85.00 | $3,031,865 | 0 | — | |
| Sep 1, 2026 DForm 4 → | Sep 1, 4:54 pm EDT | Stephen F. BetzChief Scientific Officer | 137,936 | $85.00 | $11,724,560 | 0 | — | |
| Sep 1, 2026 DForm 4 → | Sep 1, 4:53 pm EDT | Tobin SchilkeChief Financial & Infra. Ofcr. | 79,427 | $85.00 | $6,751,295 | 0 | — | |
| Sep 1, 2026 DForm 4 → | Sep 1, 4:52 pm EDT | Richard Scott StruthersPresident & CEO, Director | 1,402,911 | $85.00 | $119,247,435 | 0 | — | |
| Aug 20, 2026 AForm 4 → | Aug 24, 4:52 pm EDT | Tobin SchilkeChief Financial & Infra. Ofcr. | 471 | — | — | 79,427 | — | |
| Aug 7, 2026 MForm 4 → | Aug 11, 4:11 pm EDT | Richard Scott StruthersPresident & CEO, Director | 19,928 | $20.07 | $399,988 | 424,706 | — | |
| Jul 2, 2026 SForm 4 → | Jul 7, 4:30 pm EDT | Coelho Rogerio VivaldiDirector | 3,000 | $40.00 | $120,000 | 19,225 | −13.5% | 10b5-1 |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2026 DForm 4 → | Sep 1, 5:02 pm EDT | Wendell WierengaDirector | 110,080 | $59.08 | $6,503,719 | 0 | — | |
| Sep 1, 2026 DForm 4 → | Sep 1, 5:02 pm EDT | Coelho Rogerio VivaldiDirector | 93,830 | $55.70 | $5,226,557 | 0 | — | |
| Sep 1, 2026 DForm 4 → | Sep 1, 5:01 pm EDT | Stephanie OkeyDirector | 105,080 | $57.91 | $6,085,544 | 0 | — | |
| Sep 1, 2026 DForm 4 → | Sep 1, 5:01 pm EDT | Weston NicholsDirector | 110,080 | $59.08 | $6,503,719 | 0 | — | |
| Sep 1, 2026 DForm 4 → | Sep 1, 5:01 pm EDT | Matthew K FustDirector | 52,172 | $54.29 | $2,832,519 | 0 | — | |
| Sep 1, 2026 DForm 4 → | Sep 1, 5:00 pm EDT | Caren DeardorfDirector | 89,455 | $58.69 | $5,250,051 | 0 | — | |
| Sep 1, 2026 DForm 4 → | Sep 1, 5:00 pm EDT | Camille L BedrosianDirector | 110,080 | $60.71 | $6,682,594 | 0 | — | |
| Sep 1, 2026 DForm 4 → | Sep 1, 4:55 pm EDT | Isabel KalofonosChief Commercial Officer | 152,500 | $43.26 | $6,596,525 | 0 | — | |
| Sep 1, 2026 DForm 4 → | Sep 1, 4:54 pm EDT | Stephen F. BetzChief Scientific Officer | 767,304 | $62.55 | $47,993,850 | 0 | — | |
| Sep 1, 2026 DForm 4 → | Sep 1, 4:53 pm EDT | Tobin SchilkeChief Financial & Infra. Ofcr. | 130,000 | $47.39 | $6,160,500 | 0 | — | |
| Sep 1, 2026 DForm 4 → | Sep 1, 4:52 pm EDT | Richard Scott StruthersPresident & CEO, Director | 1,939,822 | $56.53 | $109,658,984 | 0 | — | |
| Aug 7, 2026 MForm 4 → | Aug 11, 4:11 pm EDT | Richard Scott StruthersPresident & CEO, Director | 19,928 | — | — | 244,205 | — |